Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
184 hedge funds and large institutions have $2.41B invested in Array Biopharma Inc in 2017 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 35 closing their positions.
70% more capital invested
Capital invested by funds: $1.41B → $2.41B (+$993M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 35
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
1% more funds holding
Funds holding: 182 → 184 (+2)
5% more call options, than puts
Call options by funds: $32.6M | Put options by funds: $31.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$33.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$33.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$19.4M |
| 3 |
Renaissance Technologies
New York
|
-$8.29M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$7.06M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.93M |
ARRY Hedge Fund Activity: Q3 2017 in Review
184 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2017, worth a combined $2.41B — up 70% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ARRY positions and 35 closed out — a net gain of 5 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $61.3M. The largest seller was Millennium Management, cutting an estimated $33.7M.
- 184 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2017, up from 182 in Q2 2017.
- Funds reported $2.41B of Array Biopharma Inc stock for Q3 2017, up 70% quarter-over-quarter.
- 40 funds opened new Array Biopharma Inc positions in Q3 2017 and 35 closed out, a net change of +5 holders.
- The largest Array Biopharma Inc buyer in Q3 2017 was Point72 Asset Management, an estimated $61.3M added.
- The largest Array Biopharma Inc seller in Q3 2017 was Millennium Management, an estimated $33.7M sold.
Based on aggregated 13F filings for Q3 2017.